New treatments to improve memory in Alzheimer's disease

Development of Novel Small molecule modulators of synaptic plasticity for the treatment of AD-induced cognitive decline

NIH-funded research Encue INC. · NIH-11007127

This study is testing a new medication called JB2 to see if it can help improve memory and learning by boosting brain health in people with early Alzheimer's disease.

Quick facts

Grant typeSbir 1 grant
Study typeNIH-funded research
Funding institutionEncue INC. NIH-funded
Lab location1 site (Evanston, United States)
Project IDNIH-11007127 on NIH RePORTER

What this research studies

This research focuses on developing a new small molecule, JB2, that aims to enhance synaptic plasticity, which is crucial for learning and memory. By targeting the insulin-like growth factor 2 receptor (IGF2R), JB2 seeks to restore synaptic health in the early stages of Alzheimer's disease (AD). The approach involves understanding how JB2 can activate specific receptors in the brain to improve cognitive function and potentially slow down the progression of AD. Patients may be monitored for changes in memory and cognitive abilities as part of the research.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with early-stage Alzheimer's disease who are experiencing cognitive decline.

Not a fit: Patients with advanced Alzheimer's disease or those with other forms of dementia may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that significantly improve memory and cognitive function in patients with Alzheimer's disease.

How similar studies have performed: Previous research has shown promise in enhancing synaptic plasticity as a therapeutic target for Alzheimer's disease, suggesting potential for success with this novel approach.

Where this research is happening

Evanston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementia
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.